Methylprednisolone in cis-platinum induced nausea and emesis: A placebo-controlled trial

Craig A. Metz, Ralph S. Freedman, Javier F. Magrina

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In a double-blind, placebo-controlled trial, the antiemetic efficacy of a total of 1-2 g methylprednisolone sodium succinate (MPSS) alone versus placebo was evaluated over the first three courses of chemotherapy in a group of 27 women receiving moderate to high-dose cis-platinum (50-118 mg/m2) for ovarian or cervical carcinomas. Antiemetic protection was classified as total (no emesis), major (one or two bouts), minor (three to five bouts), or minimal (six or more bouts). Total or major protection occurred in 10 26 (38.5%) of the MPSS cycles and in 6 24 (25%) of the placebo cycles (NS). A significant number of placebo patients ( 7 14 placebo versus 1 13 MPSS, P = 0.02) dropped out of the study due to lack of efficacy. Patient evaluations completed 24 hr before and after each course of chemotherapy indicated no treatment effect on pain, appetite, nausea, drowsiness, anxiety, sense of well-being, or sleep. Physician and patient global evaluations of antiemetic efficacy favored treatment with MPSS. Evidence of the efficacy of single-drug MPSS antiemetic therapy during non-cis-platinum or low-dose cis-platinum (<50 mg/m2) chemotherapy can be found in the literature. The results of this study, however, do not support the use of MPSS alone with high-dose cis-platinum chemotherapy.

Original languageEnglish (US)
Pages (from-to)84-89
Number of pages6
JournalGynecologic Oncology
Volume27
Issue number1
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Methylprednisolone Hemisuccinate
Methylprednisolone
Nausea
Cisplatin
Vomiting
Antiemetics
Placebos
Drug Therapy
Sleep Stages
Appetite
Platinum
Sleep
Anxiety
Carcinoma
Physicians
Pain
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Methylprednisolone in cis-platinum induced nausea and emesis : A placebo-controlled trial. / Metz, Craig A.; Freedman, Ralph S.; Magrina, Javier F.

In: Gynecologic Oncology, Vol. 27, No. 1, 1987, p. 84-89.

Research output: Contribution to journalArticle

Metz, Craig A. ; Freedman, Ralph S. ; Magrina, Javier F. / Methylprednisolone in cis-platinum induced nausea and emesis : A placebo-controlled trial. In: Gynecologic Oncology. 1987 ; Vol. 27, No. 1. pp. 84-89.
@article{0dccbdabfa2b472fadb9a78d98e9eb0d,
title = "Methylprednisolone in cis-platinum induced nausea and emesis: A placebo-controlled trial",
abstract = "In a double-blind, placebo-controlled trial, the antiemetic efficacy of a total of 1-2 g methylprednisolone sodium succinate (MPSS) alone versus placebo was evaluated over the first three courses of chemotherapy in a group of 27 women receiving moderate to high-dose cis-platinum (50-118 mg/m2) for ovarian or cervical carcinomas. Antiemetic protection was classified as total (no emesis), major (one or two bouts), minor (three to five bouts), or minimal (six or more bouts). Total or major protection occurred in 10 26 (38.5{\%}) of the MPSS cycles and in 6 24 (25{\%}) of the placebo cycles (NS). A significant number of placebo patients ( 7 14 placebo versus 1 13 MPSS, P = 0.02) dropped out of the study due to lack of efficacy. Patient evaluations completed 24 hr before and after each course of chemotherapy indicated no treatment effect on pain, appetite, nausea, drowsiness, anxiety, sense of well-being, or sleep. Physician and patient global evaluations of antiemetic efficacy favored treatment with MPSS. Evidence of the efficacy of single-drug MPSS antiemetic therapy during non-cis-platinum or low-dose cis-platinum (<50 mg/m2) chemotherapy can be found in the literature. The results of this study, however, do not support the use of MPSS alone with high-dose cis-platinum chemotherapy.",
author = "Metz, {Craig A.} and Freedman, {Ralph S.} and Magrina, {Javier F.}",
year = "1987",
doi = "10.1016/0090-8258(87)90233-2",
language = "English (US)",
volume = "27",
pages = "84--89",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Methylprednisolone in cis-platinum induced nausea and emesis

T2 - A placebo-controlled trial

AU - Metz, Craig A.

AU - Freedman, Ralph S.

AU - Magrina, Javier F.

PY - 1987

Y1 - 1987

N2 - In a double-blind, placebo-controlled trial, the antiemetic efficacy of a total of 1-2 g methylprednisolone sodium succinate (MPSS) alone versus placebo was evaluated over the first three courses of chemotherapy in a group of 27 women receiving moderate to high-dose cis-platinum (50-118 mg/m2) for ovarian or cervical carcinomas. Antiemetic protection was classified as total (no emesis), major (one or two bouts), minor (three to five bouts), or minimal (six or more bouts). Total or major protection occurred in 10 26 (38.5%) of the MPSS cycles and in 6 24 (25%) of the placebo cycles (NS). A significant number of placebo patients ( 7 14 placebo versus 1 13 MPSS, P = 0.02) dropped out of the study due to lack of efficacy. Patient evaluations completed 24 hr before and after each course of chemotherapy indicated no treatment effect on pain, appetite, nausea, drowsiness, anxiety, sense of well-being, or sleep. Physician and patient global evaluations of antiemetic efficacy favored treatment with MPSS. Evidence of the efficacy of single-drug MPSS antiemetic therapy during non-cis-platinum or low-dose cis-platinum (<50 mg/m2) chemotherapy can be found in the literature. The results of this study, however, do not support the use of MPSS alone with high-dose cis-platinum chemotherapy.

AB - In a double-blind, placebo-controlled trial, the antiemetic efficacy of a total of 1-2 g methylprednisolone sodium succinate (MPSS) alone versus placebo was evaluated over the first three courses of chemotherapy in a group of 27 women receiving moderate to high-dose cis-platinum (50-118 mg/m2) for ovarian or cervical carcinomas. Antiemetic protection was classified as total (no emesis), major (one or two bouts), minor (three to five bouts), or minimal (six or more bouts). Total or major protection occurred in 10 26 (38.5%) of the MPSS cycles and in 6 24 (25%) of the placebo cycles (NS). A significant number of placebo patients ( 7 14 placebo versus 1 13 MPSS, P = 0.02) dropped out of the study due to lack of efficacy. Patient evaluations completed 24 hr before and after each course of chemotherapy indicated no treatment effect on pain, appetite, nausea, drowsiness, anxiety, sense of well-being, or sleep. Physician and patient global evaluations of antiemetic efficacy favored treatment with MPSS. Evidence of the efficacy of single-drug MPSS antiemetic therapy during non-cis-platinum or low-dose cis-platinum (<50 mg/m2) chemotherapy can be found in the literature. The results of this study, however, do not support the use of MPSS alone with high-dose cis-platinum chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0023190142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023190142&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(87)90233-2

DO - 10.1016/0090-8258(87)90233-2

M3 - Article

C2 - 3552909

AN - SCOPUS:0023190142

VL - 27

SP - 84

EP - 89

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -